Three days later, we analyzed the immune profile within tumors and tumor-draining lymph nodes and found that Bic-Exo administration elicited an enhanced antitumor immune response, characterized by augmented immune response in tumor-draining lymph nodes (Supplemental Figure 15, D–F) as well as increased presence of overall CD45+ immune cells (Supplemental Figure 15G) and cytotoxic CD8+ T cells in tumor tissues (Supplemental Figure 15, H–J). The gene discussed is PTPRC; the disease is neoplasm.